Evaluation of Bumetanide’s Effect on Symptom Characteristics in Patients with Obsessive Compulsive Disorder

Evaluation of Bumetanide’s Effect on Symptom Characteristics ( Based on YBOCS) in Patients with Resistant Obsessive Compulsive Disorder Comparing to Selective Serotonin Reuptake Inhibitors

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140120016280N3

Enrollment

Registered

2019-08-11

Start date

2019-08-23

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder (OCD). Obsessive-compulsive disorder

Interventions

Intervention 1: Resistant Patient Group that receive Bumetanide in addition to the background Serotonin Reuptake Inhibitors (SRIs). Bumetanide, 3-butylamino-4-phenoxy-5-sulfamoylbenzoic acid, which is

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed Diagnosis of Resistant OCD Age range of 18-50 years IQ level more than 80 based on Wechsler Adult Intelligence Scale

Exclusion criteria

Exclusion criteria: Comorbidities like MDD, Bipolar Disorder, Personality Disorder, Schizophrenia Drug Adverse Effects Pregnancy, Breast Feeding (Based on self report data and urinary detection) Drug and alcohol use and dependance (Based on self report data and urinary detection) Benzodiazepine use within 3 preceding months Furesemide and other diuretic and cardiovascular drugs use Sulfur and its derivatives sensitivity Neurological Disorders(seizure, trauma, ischemic stroke, surgery) Presence of MRI SCanning absolute and partial contraindications

Design outcomes

Primary

Measure	Time frame
Symptom (Obsession and Compulsions) Severity Based on Yale Brown Obsessive Compulsive Disorder Scale. Timepoint: Assessment of Severity and pattern of symptoms : 1. In the beginning of Study and before intervention, 2. 10 days after intervention, 3. 20 days after intervention, 4. 30 days after intervention, 5. 40 days after intervention, 6. 50 days after intervention, 7. 60 days after intervention, 8. 70 days after intervention. Method of measurement: Validated Yale Brown Obsessive Compulsive Disorder Scale.	—

Measure

Time frame

Symptom (Obsession and Compulsions) Severity Based on Yale Brown Obsessive Compulsive Disorder Scale. Timepoint: Assessment of Severity and pattern of symptoms : 1. In the beginning of Study and before intervention, 2. 10 days after intervention, 3. 20 days after intervention, 4. 30 days after intervention, 5. 40 days after intervention, 6. 50 days after intervention, 7. 60 days after intervention, 8. 70 days after intervention. Method of measurement: Validated Yale Brown Obsessive Compulsive Disorder Scale.

—

Secondary

Measure	Time frame
Alteration in Neuro-Cognitive Functioning. Timepoint: In the Beginning of Study and then after Study Completion. Method of measurement: the Cambridge Neuropsychological Test Automated Battery (CANTAB).;Assessment of Functional Reorganization of Large Scale Brain Networks. Timepoint: Before the beginning of the clinical trial and immediately after the end of that. Method of measurement: Functional Magnetic Resonance Imaging.;Expression of Na-K-Cl Co transporter (NKCC1) in Lymphocytes of the Peripheral Blood. Timepoint: Before the Beginning of the Clinical Trial and Immediately after that. Method of measurement: Real Time Polymerase Chain Reaction (RT-PCR) and Western Analysis.;Expression of K-Cl Co transporter in lymphocyte of the peripheral blood. Timepoint: Before the beginning of the Clinical Trial and Immediately after that. Method of measurement: Real Time Polymerase Chain Reaction (RT-PCR) and Western Analysis.	—

Measure

Time frame

Alteration in Neuro-Cognitive Functioning. Timepoint: In the Beginning of Study and then after Study Completion. Method of measurement: the Cambridge Neuropsychological Test Automated Battery (CANTAB).;Assessment of Functional Reorganization of Large Scale Brain Networks. Timepoint: Before the beginning of the clinical trial and immediately after the end of that. Method of measurement: Functional Magnetic Resonance Imaging.;Expression of Na-K-Cl Co transporter (NKCC1) in Lymphocytes of the Peripheral Blood. Timepoint: Before the Beginning of the Clinical Trial and Immediately after that. Method of measurement: Real Time Polymerase Chain Reaction (RT-PCR) and Western Analysis.;Expression of K-Cl Co transporter in lymphocyte of the peripheral blood. Timepoint: Before the beginning of the Clinical Trial and Immediately after that. Method of measurement: Real Time Polymerase Chain Reaction (RT-PCR) and Western Analysis.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahmoudreza Hadjighassem

Tehran University of Medical Sciences

mhadjighassem@tums.ac.ir+98 02143052000 , +98 02188991102

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026